Americas - EMEA - APAC Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Pfizer Inc. - Regeneron Pharmaceuticals Inc. - Valeant Pharmaceuticals International Inc. Other Prominent Vendors - Abbott Laboratories Ltd
March 25 (Reuters) - U.S. health regulators on Wednesday approved Regeneron Pharmaceuticals Inc's big-selling eye drug Eylea to treat diabetic retinopathy, the most common diabetic eye disease and a leading cause of blindness in adults.
anti-VEGF treatments that require monthly injections (Roche's RHHBY Lucentis) and bimonthly injections (Regeneron's REGN Eylea). We think the first DARPin molecule is likely to enter Phase III trials by 2016. Molecular Partners can earn as much
NFLX, DIS, NVS, M, Tencents/700.hk/TCEHY, FCA.it/FCAU, GILD, CVS, TJX, RYA.ir/RYAAY, GOOGL, UA, HDB, REGN , SBUX, FDX, SoftBank/9984.ja/SFTBY, ICE, ABT, Fast Retailing/9983.ja/FRCOY, Lenovo/992.hk/LNVGY, FB
for wet age-related macular degeneration and diabetic macular degeneration have been wildly successful, with Regeneron 's REGN and Bayer 's BAYRY Eylea and Novartis ' NVS and Roche 's RHHBY Lucentis both easily reaching blockbuster status. Other eye
Holdings [ CPA ] is attractive for a rebound play. Strong large-cap performers with significant insider activity include KMI, REGN , RSG, VRX, CHTR, DVA, TWX . For the week , DJIA -1.22% , SP500 -1.46% , Nasdaq Comp -1.67% , Russell 2000
Stefan Quenneville: Regeneron ( REGN ) is a biotechnology company that we rate as having a narrow moat and a positive moat trend. We think its positive moat trend
Can anyone provide some insight on why they think this company would be a Great Investment? Thank you for the input!
Some of his biggest winners in recent years are shares he bought years ago when they were much smaller, including Regeneron REGN and Salesforce.com CRM. Wymer has beaten large-growth peers during his tenure, albeit with greater volatility. Wymer doesn
relative to sectors such as IT that require lesser capex. Some highflyers sank last week, e.g. biotechs [ ALXN, CELG, GILD, REGN ] and other momentum favorites [ GMCR, FB, TWTR, P, YELP, NFLX, BIDU ]; fears of higher rates and weaker economy were